Loading clinical trials...
Loading clinical trials...
A Randomized Trial of Rituximab in Induction Therapy for Living Donor Renal Transplantation
Hypothesis: * That B cell depletion, rather than reducing acute rejection, will allow minimisation of immunosuppression, which may lead to better graft survival. Aim: * To assess whether the addition of rituximab to a low-dose tacrolimus immunosuppression regime allows a reduction in steroid administration. Objectives: * To assess whether B cell depletion affects graft function, acute rejection and complication rates * To assess whether the T cell response to allotransplantation is impaired by B cell depletion.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
South West Transplant Centre
Plymouth, Devon, United Kingdom
East Kent Hospitals NHS Foundation Trust
Canterbury, Kent, United Kingdom
Glasgow Renal and Transplant Unit
Glasgow, United Kingdom
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom
Central Manchester University Hospitals NHS Foundation Trust
Manchester, United Kingdom
Sheffield Kidney Institute
Sheffield, United Kingdom
Start Date
November 1, 2010
Primary Completion Date
October 1, 2020
Completion Date
October 1, 2022
Last Updated
July 22, 2020
100
ACTUAL participants
Rituximab
DRUG
Tacrolimus
DRUG
Mycophenylate mofetil
DRUG
Hydrocortisone
DRUG
Prednisolone
DRUG
Prednisolone
DRUG
Lead Sponsor
Guy's and St Thomas' NHS Foundation Trust
Collaborators
NCT02658162
NCT01513707
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT02490202